Navigation Links
Sexual Function Affected by Stem Cell Transplant According to Long-Term Study
Date:9/18/2007

WASHINGTON, Sept. 18 /PRNewswire-USNewswire/ -- A long-term study found that a type of stem cell transplant used for patients with life-threatening diseases, such as leukemia and lymphoma, results in decreased sexual function and activity for recipients. Further, males are likely to recover from these changes over time, while the sexuality of female patients remains compromised. In addition, neither male nor female long-term cancer survivors regained levels of sexual activity and function equal to those of their peers who have not had cancer, according to a Blood First Edition Paper prepublished online today. Blood is the official journal of the American Society of Hematology.

"Survival without a sex life should not be what cancer survivors settle for or what health-care professionals consider a successful outcome of cancer treatment," stated lead study author, Karen Syrjala, PhD, co-director of the Survivorship Program at the Fred Hutchinson Cancer Research Center. "Sexual dysfunction in survivors of cancer needs to become a priority for research funding and a routine topic of discussion between doctors and their patients after cancer treatment."

In an allogeneic hematopoeitic stem cell transplantation, patients with diseases of the blood, bone marrow, or certain types of cancers receive an infusion of new stem cells from a sibling or tissue-matched unrelated donor to replace the damaged or destroyed cells in their bone marrow needed for the production of blood cells. Before the transplant, high-dose chemotherapy is administered to kill residual cancer cells and to suppress the immune system so that the patient's body will not reject the new tissue.

The results of questionnaires on sexual function were reported for 161 patients scheduled to receive this procedure at the Fred Hutchinson Cancer Research Center in Seattle. The patients ranged in age from 22-64 years with an average age of 41 and a nearly even split by gender.

Before the
'/>"/>

SOURCE American Society of Hematology
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Palatin Technologies and King Pharmaceuticals Report Data Showing Improvements in Sexual Relationship and Self-Esteem in Patients with Erectile Dysfunction Treated with Bremelanotide
2. An Investigational Study Released at ADA Showed that Initial Combination Therapy with Januvia (sitagliptin) and Metformin Led to Improvement in Markers of Beta Cell Function in Patients with Type 2 Diabetes
3. Research Documents Scalable Production, Survival Following Engraftment and Positive Impact on Cardiac Function in Infarcted Rats for Gerons Human Embryonic Stem Cell-Based Therapeutic for Heart Failure
4. Data Showing that ReGens Colostrinin Supports Healthy Cognitive Function Presented at the 2007 International Congress on Natural Medicine in Australia
5. Data Suggest Cymbalta Improved Functioning in Patients with Generalized Anxiety Disorder
6. Palatin Technologies and King Pharmaceuticals Announce Plan To Present Results of Bremelanotide Phase 2b Studies in Men With Erectile Dysfunction
7. Early Results of the CellCept Spare the Nephron Study Examine Kidney Function
8. Revolutionary Immunologic Data Explains Function of Diamyd Diabetes Vaccine
9. EPIX Pharmaceuticals Announces Statistically Significant Results in Cognitive Function from Phase 1b Clinical Trial of Novel 5-HT6 Drug Candidate
10. Pharmacyclics Identifies Functional Biomarkers for its Novel HDAC Inhibitor and Demonstrates Preclinical Anti-Tumor Activity with Brutons Tyrosine Kinase Inhibitors
11. Ceregene Presents Long Term Follow-Up Data From Phase 1 Trial of CERE-120 Demonstrating Improved Motor Function in Parkinsons Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)... 22, 2014 Sanomedics International Holdings, Inc. (OTCQB: ... Global Research & Data Services, demand for thermometers is ... through 2018, as demand for more accurate digital thermometers ... the world,s largest market for thermometers, and one of ... Sanomedics International Holdings, Inc. Sanomedics International Holdings ...
(Date:10/22/2014)... NEW YORK , Oct. 22, 2014 ... and dermatology therapies. PV-10, its novel investigational drug for ... the potential for systemic side effects. Its oncology focus ... liver. Provectus has completed phase 2 trials of PV-10 ... as a topical treatment for atopic dermatitis and psoriasis. ...
(Date:10/22/2014)... LA JOLLA, Calif. , Oct. 22, ... RGLS ), a biopharmaceutical company leading ... targeting microRNAs, today announced that it has ... from an ongoing clinical study evaluating RG-101, ... for the treatment of hepatitis C virus ...
Breaking Medicine Technology:Sanomedics International Holdings Analyst Report: Taking Some Heat by BrokerBank Securities, Inc. 2Provectus Biopharmaceuticals Looks at the Asian Markets: Analyst Coverage by Small Cap Traders 2A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 2A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 3A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 4A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 5A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 6A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 7A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 8
... REO, a leading manufacturer of high volume ... to the newly created position of Vice President of ... aspects of the company,s optics fabrication, thin film coating ... served with Intel Corporation developing and implementing multiple technology ...
... 14 While Father,s Day gifts range from the touching ... is help and support during the difficult time of a cancer diagnosis. ... Often men have tremendous difficulties deciding ... Michael Diefenbach , Ph.D., associate professor of Urology at Mount Sinai School ...
Cached Medicine Technology:Mark Notarfrancesco Joins REO as VP Manufacturing Operations 2Prostate Cancer: The Father's Day Gift You Never Thought About 2
(Date:10/22/2014)... (PRWEB) October 22, 2014 On Saturday, October ... its fourth annual family health and fitness fair ¡Vive tu ... physical activity and good nutrition for better health and wellness ... which is free and open to the public, will be ... Brownsville, from 9:00 am to 1:00 pm. , “¡Vive ...
(Date:10/22/2014)... (PRWEB) October 22, 2014 For Dr. Iris ... make money; it’s an extension of her life’s mission. Her ... venture as the owner of FirstLight HomeCare, make it clear ... important to me that my work makes a difference in ... an entrepreneurial spirit, so after much research, I felt ready ...
(Date:10/22/2014)... The Louis W. Sullivan Institute ... distribute health information technology innovation to transform quality ... development of six key guiding principles of patient-centered ... These are an expansion of the Institute of ... is respectful of and responsive to individual patient ...
(Date:10/22/2014)... Best Cheap Hosting USA is among ... site has recently announced that iPower ( http://www.best-cheap-hosting-usa.com/go/iPower/ ) ... from around the world. , “iPower is one of ... is providing various kinds of useful products for new ... offering excellent customer service and a number of features ...
(Date:10/22/2014)... (PRWEB) October 22, 2014 Lintelus, Inc., ... Sr. Vice President of Sales, will be speaking on ... Meetings Technology Expo on October 28, at the Holiday ... hosting a booth as well as a Tech Demo ... Meeting can create a more engaging event experience. , ...
Breaking Medicine News(10 mins):Health News:Brownsville Community Health Center Presents Fourth Annual ¡Vive Tu Vida! Get Up! Get Moving!® Event 2Health News:Brownsville Community Health Center Presents Fourth Annual ¡Vive Tu Vida! Get Up! Get Moving!® Event 3Health News:Brownsville Community Health Center Presents Fourth Annual ¡Vive Tu Vida! Get Up! Get Moving!® Event 4Health News:Dr. Iris Hunter to Host Grand Opening of FirstLight HomeCare Tomorrow 2Health News:The Sullivan Institute for Healthcare Innovation Announces Release of Guiding Principles for Patient Experience-Centered Care 2Health News:Best Cheap Hosting USA Has Recently Announced The Best Cheap Web Hosting Companies In 2014 2Health News:Jay Cormier, Sr. Vice President of Sales for Lintelus, Speaks about Event Technology Integration at Meetings Technology Expo in NYC 2
... including Parkinson's, Alzheimer's, Diffuse Lewy body disease, and ... Most commonly they become symptomatic due to a ... case of Parkinson's it is dopamine. When the ... impaired, which occurs with oxidation, the eventual results ...
... to diagnose and many a times the diagnosis is ... emerging as a promising technique for early diagnosis of ... facilitating rapid amplification of small amounts of a genome ... Urology Congress in India. Presence of even one ...
... (PPA),is a common ingredient found in many non-prescription cough ... remedies increased the risk of stroke by 23 percent. ... says, "Case reports have linked exposure to PPA to ... ,A hemorrhagic stroke results when an artery wall ruptures ...
... of India has successfully undergone left knee joint replacement by ... "The operation, which started at around 10 a.m., was completed ... satisfaction," Dr. Ranawat said at a press briefing. ``He (Mr. ... now in the recovery room. He is not on any ...
... injectable contraceptive pill has been approved by the Food ... than 99 percent effective when women get the shot ... the pill., ,Lunelle is an alternative to another ... works Like many other birth control pills as it ...
... that more than two-thirds of births in Russia are marred ... clinic is suffering health problems. , ,The number of ... 30 percent last year, said Olga Frolova, head of the ... that the decline is due to the spread of heavy ...
Cached Medicine News:
Used for placement of choledochoscopes, cholangiography catheters and other instruments. Supplied sterile in peel-open packages. Intended for one-time use....
... for cholangiography and bile ... Dual lumen catheter design ... imaging and wire basket ... Supplied sterile in peel-open ...
... the MAMMOTOME® HH (Hand Held) ... procedure using ultrasound imaging for ... to locate breast abnormalities, you ... map the area you will ...
... Provides a more occlusive wrap than ... where wound transudate must be contained. Predictable ... be inert, nonantigenic, and nonpyrogenic. ,VICRYL (polyglactin ... synthetic absorbable copolymer of glycolide and lactide, ...
Medicine Products: